518 related articles for article (PubMed ID: 27564404)
21. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
22. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
23. The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma.
Shinchi Y; Ishizuka S; Komohara Y; Matsubara E; Mito R; Pan C; Yoshii D; Yonemitsu K; Fujiwara Y; Ikeda K; Tamada K; Sakagami T; Suzuki M
Cancer Immunol Immunother; 2022 Nov; 71(11):2645-2661. PubMed ID: 35352168
[TBL] [Abstract][Full Text] [Related]
24. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
25. Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer.
Zhang GQ; Jiao Q; Shen CT; Song HJ; Zhang HZ; Qiu ZL; Luo QY
Cancer Sci; 2021 Mar; 112(3):997-1010. PubMed ID: 33247999
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
[TBL] [Abstract][Full Text] [Related]
27. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
28. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma.
Kawashima M; Carreras J; Higuchi H; Kotaki R; Hoshina T; Okuyama K; Suzuki N; Kakizaki M; Miyatake Y; Ando K; Nakayama M; Umezu S; Horie R; Higuchi Y; Katagiri K; Goyama S; Kitamura T; Chamoto K; Yano S; Nakamura N; Kotani A
Leukemia; 2020 Sep; 34(9):2405-2417. PubMed ID: 32089543
[TBL] [Abstract][Full Text] [Related]
29. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
30. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.
Song TL; Nairismägi ML; Laurensia Y; Lim JQ; Tan J; Li ZM; Pang WL; Kizhakeyil A; Wijaya GC; Huang DC; Nagarajan S; Chia BK; Cheah D; Liu YH; Zhang F; Rao HL; Tang T; Wong EK; Bei JX; Iqbal J; Grigoropoulos NF; Ng SB; Chng WJ; Teh BT; Tan SY; Verma NK; Fan H; Lim ST; Ong CK
Blood; 2018 Sep; 132(11):1146-1158. PubMed ID: 30054295
[TBL] [Abstract][Full Text] [Related]
32. Potential anti-lymphoma effect of M-CSFR inhibitor in adult T-cell leukemia/lymphoma.
Komohara Y; Noyori O; Saito Y; Takeya H; Baghdadi M; Kitagawa F; Hama N; Ishikawa K; Okuno Y; Nosaka K; Seino KI; Matsuoka M; Suzu S
J Clin Exp Hematop; 2018; 58(4):152-160. PubMed ID: 30541986
[TBL] [Abstract][Full Text] [Related]
33. Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation.
Kinch A; Sundström C; Baecklund E; Backlin C; Molin D; Enblad G
Leuk Lymphoma; 2019 Feb; 60(2):376-384. PubMed ID: 30033844
[TBL] [Abstract][Full Text] [Related]
34. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of STAT3/PD-L1 and Activation of miR193a-5p Are Critically Involved in Apoptotic Effect of Compound K in Prostate Cancer Cells.
Lee JH; Lee DY; Lee HJ; Im E; Sim DY; Park JE; Park WY; Shim BS; Kim SH
Cells; 2021 Aug; 10(8):. PubMed ID: 34440920
[TBL] [Abstract][Full Text] [Related]
36. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
37. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
[TBL] [Abstract][Full Text] [Related]
38. Targeting the programmed death-1 pathway in lymphoid neoplasms.
Ok CY; Young KH
Cancer Treat Rev; 2017 Mar; 54():99-109. PubMed ID: 28242522
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Lesokhin AM; Ansell SM; Armand P; Scott EC; Halwani A; Gutierrez M; Millenson MM; Cohen AD; Schuster SJ; Lebovic D; Dhodapkar M; Avigan D; Chapuy B; Ligon AH; Freeman GJ; Rodig SJ; Cattry D; Zhu L; Grosso JF; Bradley Garelik MB; Shipp MA; Borrello I; Timmerman J
J Clin Oncol; 2016 Aug; 34(23):2698-704. PubMed ID: 27269947
[TBL] [Abstract][Full Text] [Related]
40. Total Glucosides of Paeony Ameliorate Pristane-Induced Lupus Nephritis by Inducing PD-1 ligands
Liang CL; Jiang H; Feng W; Liu H; Han L; Chen Y; Zhang Q; Zheng F; Lu CJ; Dai Z
Front Immunol; 2021; 12():683249. PubMed ID: 34290705
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
